ALSO NOTED: Vasogen to complete Phase III trials this year; Viventia to go private; and much more...

> Canada's Vasogen said that the biggest of its ongoing Phase III trials for Celacade for heart failure will be completed by the end of the year. Report

> Viventia Biotech of Toronto has struck a deal to go private. Report

> Merck has received FDA approval to expand the use of Invanz for diabetic foot infections. Article

> The European Medicines Agency granted Pharmaxis orphan status for Bronchitol for the treatment of cystic fibrosis. Release

> Australia's Pharmaxis has raised $87 million in new capital. Release

> Hana Biosciences of South San Francisco has posted positive interim results for a Phase I study of Talotrexin (PT-523) in relapsed or refractory advanced non-small cell lung cancer. Release

And Finally... Impax Laboratories has filed a fresh complaint against Shire in their dispute over Adderall XR. Report